The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Shailly Gupta, Communications Advisor, MSF Access Campaign, speaks at the opening of the 2023 World Health Assembly, about the access issues MSF is advocating on this year.